Day One Biopharmaceuticals, Inc. (DAWN)
| Previous Close | 15.01 |
| Open | 15.00 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's Range | 14.97 - 15.23 |
| 52 Week Range | 9.67 - 18.07 |
| Volume | |
| Avg. Volume | 994,045 |
| Market Cap | 1.49B |
| Beta (5Y Monthly) | -1.52 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.94 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 39.38 |
Insider MonkeyDay One Biopharmaceuticals (DAWN): Advancing Targeted Therapies for Pediatric Glioma
We recently published a list of 10 Biggest Stocks with Negative Beta to Consider. In this article, we are going to take a look at where Day One Biopharmaceuticals (NASDAQ:DAWN) stands against other biggest stocks with negative beta to consider. Beta is a measureament of market risk or volatility that indicates how much the price […]
GlobeNewswireDay One to Report Third Quarter 2024 Financial Results Wednesday, October 30, 2024
BRISBANE, Calif., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced it will host a live conference call and webcast on Wednesday, October 30, 2024 at 4:30 p.m. ET to report financial results and discuss corporate progress for the third quarter 2024. Live audio of the webcast will b
